Marksans Pharma is currently trading at Rs. 49.25, up by 1.45 points or 3.03% from its previous closing of Rs. 47.80 on the BSE.
The scrip opened at Rs. 48.00 and has touched a high and low of Rs. 51.70 and Rs. 45.65 respectively. So far 3735769 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 58.25 on 11-Apr-2017 and a 52 week low of Rs. 35.75 on 11-Aug-2017.
Last one week high and low of the scrip stood at Rs. 51.70 and Rs. 42.40 respectively. The current market cap of the company is Rs. 2017.92 crore.
The promoters holding in the company stood at 48.25%, while Institutions and Non-Institutions held 8.82% and 42.93% respectively.
Marksans Pharma has received Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its Goa facility which was inspected between April 3 and April 7, 2017.
Marksans Pharma is engaged in production of prescription drugs, caters in areas like oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others.
